AbbVie Redeems Priority Review Voucher for Rinvoq Approval

On Thursday afternoon, the U.S. Food and Drug Administration published in the Federal Register that AbbVie has redeemed a Rare Pediatric Disease Priority Review Voucher for Rinvoq (upadactinib). The FDA approved the drug in March for adults with moderately to severely active ulcerative colitis (UC) who didn’t respond adequately or were intolerant to one or more tumor necrosis factor (TNF) blockers.